How can clinical trial sponsors employ genomic data insights to propel patient-centered drug discovery and development?
CS1002 plus CS1003 showed promising antitumor activity and had a manageable safety profile across a broad dosing range in trials
Phase 2 trial results indicate benefits of the new way of treating advanced ER+ breast cancer
The team’s next step is to introduce immunotherapy to treat soft tissue sarcomas
Researchers identified characteristics of donated cord blood units associated with strong clinical responses in the Phase 1/2 trial
New research introduces CAR-T cells that flourish in tumor environments, greatly advancing cancer immunotherapies
Through this work, researchers encourage using liquid biopsies in clinical decision-making
The FDA granted the approval of Ogsiveo to SpringWorks Therapeutics Inc.
Tebotelimab targets two proteins on tumor cells and drives specific immune response safely and effectively
New joint consensus manuscript from AMP developed in collaboration with ASCO and CAP